Introduction
============

Hepatocellular carcinoma (HCC) represented approximately 85-90% of the primary hepatic cancer. In China, HCC ranked fourth in the morbidity rate and third in mortality rate among all the malignancies [@B1], [@B2]. The number of HCC patients increased by over 400 thousand annually, most of whom were diagnosed at the advanced stage, which resulted in the unpleasant prognosis and relatively low 5-year survival rate [@B3]-[@B5]. Notably, Guangxi is a region with a high incidence of HCC [@B6], [@B7]. Currently, the main treatment for HCC was operation, but the operation failed to achieve satisfactory clinical cure rate and long-term survival rate [@B8], [@B9]. Therefore, the major concern is to seek novel treatments for HCC. Recently, the molecularly targeted therapy has been rising as a new approach to dealing with cancers [@B10]-[@B12]. The initiation and progression of HCC was considered a continual and complex process that involved multiple factors and stages of evolution, in which abnormal changes were detected in the structures and expressions of a large number of coding or non-coding-RNAs. In recent years, the research on the non-coding RNAs has refreshed our knowledge on the initiation and development of HCC, the early diagnostic markers and the novel therapeutic targets [@B13]-[@B15].

The microRNA (miRNA), a sort of non-coding RNA (involving around 20-22 nucleotides) without the protein coding function, affects RNA silencing and post-transcriptional regulation of gene expression [@B16], [@B17]. Several researches indicated that miRNA closely correlated to the onset and development of tumors [@B18], [@B19]. Studies by deep sequencing and gene microarrays also showed that a number of miRNA was aberrantly expressed in cancer cell lines and tumor tissues, and they participated in the biological process such as the tumor onset, development, metastasis and so on, influencing the growth and proliferation of cancer cells, invasion, metastasis, apoptosis, autophagy, etc. [@B20]-[@B24]. Thereby, the identification of miRNA in the initiation and progression of tumors could assist us to investigate the mechanism of tumor initiation and progression, and to seek the novel diagnostic markers and therapeutic targets [@B25]-[@B33].

The miR-196b-5p, which is categorized into the miR-196b family, is located on human chromosome 7p15.2. Previous studies had shown that overexpressed miR-196b-5p was observed in colorectal carcinoma [@B34] and gastric carcinoma [@B35]. In the colorectal cancer, miR-196b-5p could regulate the invasion as well as the metastasis of colorectal cancer cells by targeting HOXB7 and GALNT5 [@B36]. In terms of the research on miR-196b in the HCC, only Shen et al. [@B37] detected its overexpression in HCC, and no studies was found on the clinical value of miR-196b-5p in HCC and its mechanism. By quantitative reverse transcription and polymerase chain reaction (qRT-PCR), this study examined the expression of miR-196b-5p in the HCC tissues and the adjacent paraffin embedded tissues, and explored its clinical significance as well. Besides, for the purpose of investigating the expression of miR-196b-5p and its clinical significance in HCC, we took advantage of the RNA sequencing (RNA-seq) data in The Cancer Genome Atlas (TCGA, <https://cancergenome.nih.gov/cancer>) and microarray data in Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>). The target genes of miR-196b-5p would be predicted, and also its molecular mechanism in HCC would be explored.

Materials and Methods
=====================

Tissue samples
--------------

The researchers collected 67 cases of HCC tissues and 67 cases of corresponding adjacent paraffin embedded tissues from The First Hospital Affiliated to Guangxi Medical University between Jan. 1, 2015 and May 1, 2016. The present study was approved by the Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (Nanning, China), and written informed consent was obtained from all patients.

RNA extraction and qRT-PCR
--------------------------

According to the instruction of E.Z.N.A.TM FFPE RNA Kit of Omega Bio-Tek, we extracted the total RNA of 67 cases of HCC tissues and their corresponding adjacent tissues. The reverse transcription was conducted with miRNA 1st Strand cDNA Synthesis Kit (by stem-loop) of Vazyme Biotech Co.,Ltd. The relative quantification of miR-196b-5p expression was performed by Applied Biosystems PCR7500, with the reagent being the miRNA Universal SYBR® qPCR Master Mix of Vazyme. The sequencing of miR-196b-5p primers included F:5\' -GCGCGTAGGTAGTTTCCTGTT-3\', R:5\' - AGTGCAGGGTCCGAGGTATT-3. The sequencing of endogenous reference genes primer U6 was F: 5\'-CTCGCTTCGGCAGCACA-3\', R: 5\'- AACGCTTCACGAATTTGCGT-3\'. The expression value was calculated with 2^-ΔCt^ method.

The collection of RNA sequencing data in TCGA
---------------------------------------------

By Xena Public Data Hubs (<http://xena.ucsc.edu/public-hubs/>), the expression profiling of mature miRNA in HCC was acquired from TCGA, in which the miR-196b-5p was selected, including 369 cases of HCC tissues and 49 cases of normal liver tissues. In addition, the clinicopathologic parameters of HCC were downloaded from TCGA in order to evaluate their relationships with miR-196b-5p [@B38].

The collection of microarrays in GEO
------------------------------------

The researchers retrieved the miRNA microarrays related to HCC in GEO (<https://www.ncbi.nlm.nih.gov/geo/>) until Nov. 17, 2017 [@B39]. The search strategy was (hepatocellular OR liver OR hepatic) AND (miRNA OR microRNA). The standards for inclusion of the HCC related microarrays were as follows: (1) the cancer samples were diagnosed with HCC; (2) each microarray contained HCC cohort and the control; (3) the expression profiling of miR-196b-5p was available; (4) the species was homo sapiens. Those microarrays were excluded if (1) they failed to provide the expression profiling of miR-196b-5p; (2) they did not involve the controls; (3) their species were animals.

The prediction of target genes of miR-196b-5p
---------------------------------------------

The twelve online software were linked by miRWalk 2.0 (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>), including miRWalk, Microt4, miRanda, mirBridge, miRDB, miRMap, miRNAMap, Pictar2, PITA, RNA22, RNAhybrid and Targetscan, all of which could facilitate the forecast of target genes of miR-196b-5p. Afterwards, genes predicted by at least 5 software were preferred as the predicted genes of miR-196b-5p. We combined those predicted genes and the lowly-expressed differential genes analyzed by R language in TCGA, and selected the overlapping genes as the possible target genes of miR-196b-5p [@B40].

Annotation, pathway enrichment analysis and Protein-Protein Interaction (PPI) network construction
--------------------------------------------------------------------------------------------------

The David database (<https://david.ncifcrf.gov/>) was used for annotation and pathway enrichment analysis of the potential target genes of miR-196b-5p, involving the Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The GO annotation consists of biological process, cellular component and molecular function. Furthermore, the annotation included the Disease Ontology (DO) annotation, of which results could be generated by R 3.4.1. In order for PPI network construction, we researchers uploaded the potential target genes of miR-196b-5p to Search Tool for the Retrieval of Interacting Genes (STRING) (<https://string-db.org/cgi/input.pl>), with the confidence score \> 0.7 [@B39], [@B41], [@B42].

Statistical analysis
--------------------

In this study, we researchers examined the expression of miR-196b-5p with qRT-PCR, and calculated the expression value using 2^-△CT^ method: △CT = CT~miR-196b-5p~-CT~U6~. Each sample in triplicate was used in qRT-PCR, and the average CT value was determined. The expressed miR-196b-5p was distributed in skewness in the cancer and adjacent tissues. The Wilcoxon was applied for the test, and the median value was used as a cut-off for the high and low expressions of miR-196b-5p in HCC tissues. The categorical data, like the relationships of expressed miR-196b-5p with the clinicopathologic parameters, were dealt with the Fisher\'s exact test or χ^2^, whereas the ranked data were processed with the Kruskal-Wallis H test.

In TCGA and GEO, the expressed miR-196b-5p was shown in normal distribution in tumor and adjacent tissues, and we used the Student\'s T test to estimate the mean of the expression in the two cohorts. GraphPad Prism Version 5.0 (GraphPad Software, San Diego CA, USA; <https://www.graphpad.com>) was applied to draw the scatter diagram. In addition, the researchers utilized the receiver operating characteristic curve (ROC curve) to assess the capability of expressed miR-196b-5p to distinguish the cancer from non-cancer tissues, and the area under the curve (AUC) could be applied to quantitatively measure the capability, with great value indicating the great capability. We researchers took advantage of SSPS 22.0 to draw the individual ROC curve. In addition, Stata Version 12.0 was used to draw the summary ROC (SROC) curve which could systematically assess the capability of miR-196b-5p expression to distinguish the cancer from non-cancer tissues.

The Standard mean difference (SMD) and 95% confidence interval (95% CI) were calculated to scrutinize the expression of miR-196b-5p in HCC and the normal tissues. The heterogeneity of the Meta-analysis was represented with chi-square test of Q or inconsistency index (I^2^). When the *P* value \< 0.05 or I^2^ \> 50%, the heterogeneity obviously existed in the Meta-analysis, and then the random effects model would be used. If the *P* \> 0.05 or I^2^ \< 50%, we found no remarkable heterogeneity in the Meta- analysis, thereby employing the fixed effects model. We applied the Stata Version 12.0 (StataCorp, College Station, TX, USA; <http://www.stata.com>) to draw the forest plots and conducted sensitivity analysis of the Meta results. Following the sensitivity analysis, we excluded the studies beyond the base line, and then drew the forest plots again. On the condition that the SMD or 95%CI scarcely varied and no obvious heterogeneity was found, the results of Meta-analysis seemed valid and reliable. Besides, the publication bias of the Meta-analysis was evaluated through Egger\'s and Begg\'s tests, and then drew the funnel plots. The*P* value \> 0.05 (of Egger\'s and Begg\'s tests) would mean no publication bias existed.

Results
=======

The expression of miR-196b-5p in HCC tissues and in corresponding adjacent tissues
----------------------------------------------------------------------------------

In the study, 41 of 67 cases (61.2%) showed that higher expression of miR-196b-5p was seen in HCC tissues than in the adjacent ones. In these 67 cases, the expressed miR-196b-5p displayed skewed distribution in HCC and the adjacent tissues. In HCC tissues, the median of the relative expression of miR-196b-5p was 0.042, and the inter-quartile range was 0.020-0.404, while in the adjacent tissues, the median value was 0.037 and the inter-quartile range was 0.017-0.072. By Wilcoxon test, we ascertained that the higher relative expression of miR-196b-5p was examined in HCC rather than in adjacent tissues, with statistical significance (*P* = 0.0007) (**Figure [1](#F1){ref-type="fig"}A**). The ROC curve was applied to assess the ability of miR-196b-5p expression to differentiate between the cancer tissues and the non-cancer ones, of which result revealed that AUC was 0.615 (95%CI: 0.517-0.713, *P* = 0.022), with sensitivity being 0.388 and specificity being 0.94 (**Figure [1](#F1){ref-type="fig"}B**). The analysis of the relationships between miR-196b-5p expression and the clinicopathologic parameters revealed that the expression was associated with tumor size, nodule number, vascular and capsular invasions (*P* \< 0.05) (**Table [1](#T1){ref-type="table"}**).

The clinical significance of miR-196b-5p in HCC in TCGA
-------------------------------------------------------

From TCGA database, the researchers downloaded the expression profiling of miR-196b-5p and subsequently compared the 369 cases of HCC tissues and 49 cases of normal liver tissues, finding expression of miR-196b-5p was seen higher in HCC tissues (4.49 ± 2.42) rather than in normal tissues (3.47 ± 0.50), with statistical significance (*P* = 0.0033), (**Figure [2](#F2){ref-type="fig"}A**). The AUC of miR-196b-5p expression to discriminate cancer tissues from the non-cancer ones was 0.562 (95%CI: 0.511-0.613, *P* = 0.159), with sensitivity and specificity being 0.434 and 1 respectively (**Figure [2](#F2){ref-type="fig"}B**). The analysis of the relationships between miR-196b-5p expression and the clinicopathologic parameters proved that the expression was in a close association with the sex of patients with HCC, pathologic grading and vascular invasions (**Table [2](#T2){ref-type="table"}**).

The expression of miR-196b-5p in HCC in GEO
-------------------------------------------

Having retrieved the GEO database, we included in our research 10 microarrays of miR-196b-5p expression profiling, involving GSE6857, GSE12717, GSE21362, GSE22058, GSE31383, GSE41874, GSE54751, GSE57555, GSE69580 and GSE74618. The retrieval process was displayed in **Figure [3](#F3){ref-type="fig"}**. The basic features of these 10 microarrays were shown in **Table [3](#T3){ref-type="table"}**. In 6 microarrays, compared with the normal tissues, miR-196b-5p was expressed higher in HCC tissues (GSE6857, GSE12717, GSE21362, GSE22058, GSE54751 and GSE69580) (**Figure [4](#F4){ref-type="fig"}A-D, G, H**). However, no statistical significance was found in miR-196b-5p expression in HCC and normal liver tissues (GSE31383, GSE41874, GSE57555, GSE74618) (**Figure [4](#F4){ref-type="fig"} E, F, H, J**). The ROC curves of each microarray were displayed in **Figure [5](#F5){ref-type="fig"}**.

The analysis of miR-196b-5p expression in HCC by combination of TCGA, GEO and qRT-PCR results
---------------------------------------------------------------------------------------------

In order to systematically and holistically analyze the miR-196b-5p expression, we researchers combined the results of TCGA, GEO and qRT-PCR for Meta-analysis, which contained 1105 cases of HCC tissues and 586 cases of normal liver tissues. The Meta-analysis showed SMD = 0.62 (95%CI: 0.41-0.83); since the SMD \> 0 and 95%CI did not cover 0, it was demonstrated that miR-196b-5p displayed was expressed higher in HCC tissues rather than in normal liver tissues (**Figure [6](#F6){ref-type="fig"}**). The heterogeneity test revealed that remarkable heterogeneity was observed in Meta-analysis of miR-196b-5p expression (*P* ~heterogeneity~ = 0.012, I^2^ = 54.3%; **Figure [6](#F6){ref-type="fig"}**), so random effects model was preferred. In the sensitivity test, after excluding GSE6857 and GSE22058, we discovered SMD = 0.56 (95%CI: 0.39-0.72), and failed to detect obvious heterogeneity (*P* ~heterogeneity~ = 0.275, I^2^ = 18.3%;**Figure [7](#F7){ref-type="fig"}A, B**). Egger\'s test showed *P* = 0.230, and Begg\'s test showed *P* = 0.304; in addition, the funnel plots were distributed in symmetry, suggesting that we failed to detect remarkable publication bias in the Meta-analysis of miR-196b-5p expression (**Figure [8](#F8){ref-type="fig"}**).

The SROC curve was applied to analyze and calculate the AUC and 95%CI in order to systematically evaluate the ability of miR-196b-5p expression to distinguish the cancer tissues from the non-cancer ones. As **Figure [9](#F9){ref-type="fig"}** illustrated, the total AUC of miR-196b-5p expression was 0.80 (95%CI: 0.76-0.83), with the sensitivity being 0.58 (95%CI: 0.41-0.74) and specificity being 0.94 (95%CI: 0.78-0.98).

The potential target genes of miR-196b-5p
-----------------------------------------

We researchers predicted the target genes of miR-196b-5p with the help of twelve online softwares (miRWalk, miRanda, Microt4, mirBridge, RNA22, miRMap, miRDB, miRNAMap, Pictar2, PITA, RNAhybrid and Targetscan), and then selected 1955 genes that were predicted by at least 5 software. Subsequently, we combined these 1955 genes and 1123 down-regulated mRNAs in TCGA (Log2 Fold Change \< -1, P \< 0.05) (**Figure [10](#F10){ref-type="fig"}**), acquiring 107 overlapping potential target genes (**Table [4](#T4){ref-type="table"}**).

Annotation, pathway enrichment analysis and PPI network construction
--------------------------------------------------------------------

The DAVID database was utilized for GO annotation and KEGG pathway enrichment analysis for the purpose of exploring the functions of these 107 possible target genes of miR-196b-5p as well as the relevant molecular mechanism (**Table [5](#T5){ref-type="table"}**). The GO analysis displayed that in biological process the potential target genes mainly participated in single-organism catabolic process, response to external stimulus, single-organism metabolic process, etc. In cellular component, these potential target genes were mostly enriched in neuronal cell body, cell periphery and extracellular space. In molecular function, the potential target genes largely took part in the molecular process like transmembrane receptor protein kinase activity, 3\',5\'-cyclic-AMP phosphodiesterase activity, growth factor binding and so on. The KEGG analysis uncovered that the potential target genes were chiefly involved in pathways of tryptophan metabolism, pathways in cancer, complement and coagulation cascades, beta-alanine metabolism, prostate cancer, morphine addiction and so on. Moreover, DO annotation of the potential target genes were conducted via R 3.4.1 (**Figure [11](#F11){ref-type="fig"}**), and the top ten terms of DO annotation (based on the P value) were listed in **Figure [12](#F12){ref-type="fig"}**. Also, we constructed the PPI network of these 107 possible target genes of miR-196b-5p by STRING (**Figure [13](#F13){ref-type="fig"}**).

Discussion
==========

The miR-196b-5p, which is categorized into the miR-196b family (containing miR-196a-1, miR-196a-2 and miR-196b), is situated on human chromosome 7p15.2, which is situated in the area of homobox (HOX) gene cluster [@B43], [@B44]. The nucleotide sequence of mature miR-196a-1 is the same as that of mature miR-196a-2, but mature miR-196b and mature miR-196a varied in one nucleotide [@B44]. Abnormally expressed miR-196b was frequently detected in various tumors like head and neck squamous-cell carcinoma (HNSCC), colorectal carcinoma, lung carcinoma, pancreatic cancer, gastric cancer, etc. In HNSCC, the results of Álvarez-Teijeiro et al. suggested that miR-196b exhibited higher expression in HNSCC fresh tissues and paraffin-embedded tissues than in the adjacent ones; in addition, overexpression of miR-196b was detected in the saliva samples [@B45]. In the case of lung cancer, Bai et al. used qRT-PCR to confirm that remarkably lower expression of miR-196b appeared in various lung cancer cell lines (A549, H-1650 and H-1299) than in healthy lung tissue cells (WI-38 and HEL-1) [@B46]. In pancreatic cancer, Wang et al. examined the differentially expressed miRNAs of 20 cases of pancreatic cancer tissues and the non-cancer ones, and acquired 39 lowly expressed and 40 highly expressed miRNAs in the cancer tissues. Subsequently, qRT-PCR was used to verify the top five miRNAs: miR-200c, miR-196b, miR-1, miR-200a and let-7b (based on the P value), and it was uncovered that miR-196b, miR-200a and miR-200c were detected to be highly expressed, miR-1 was seen lowly expressed, whereas the expression of let-7b showed no statistical significance in cancer tissues and the non-cancer ones [@B47]. By ArrayExpress and TCGA, Ren et al. concluded that miR-196b-5p displayed higher expression in colorectal cancer tissues compared with normal colonic mucosa tissues [@B48]. In gastric carcinoma, Lee et al. took advantage of miRNA microarrays to examine 34 cases of gastric cancer tissues and the adjacent ones, afterwards acquiring 5 highly expressed miRNAs in cancer tissues (miR-196b-5p, miR-215, miR-375, miR-1and miR-370) and 5 lowly expressed miRNAs (miR-2861, miR-483-5p, miR-486-5p, miR-622 and miR-149-3p), and finally confirmed that the expressions of miR-196b-5p and miR-375 were consistent with the microarrays [@B35]. Studies above all suggested that the aberrantly expressed miR-196b was closely linked with morbid state.

In this research, we researchers applied qRT-PCR to examine the miR-196b-5p expression in HCC, discovering that miR-196b-5p displayed higher expression in HCC tissues than in the adjacent ones with the assistance of endogenous reference genes primer U6. The analysis of relationships between miR-196b-5p expression and the clinicopathologic parameters revealed that the expression was associated with the tumor size, nodule number, vascular and capsular invasions. Following that, we selected the miR-196b-5p from the expression profiling of mature miRNA in TCGA database, and uncovered that higher expression of miR-196b-5p was observed in HCC tissues than in healthy liver tissues; the expression was connected with the sex of patients, pathologic grading and vascular invasion. Afterwards, we researchers analyzed the miRNA microarrays in GEO, and carried out Meta-analysis of miR-196b-5p by combining the results of qRT-PCR and TCGA sequencing data, which verified that miR-196b-5p was differentially expressed and overexpressed in HCC tissues.

Results above indicated that miR-196b-5p was abnormally expressed in HCC; more importantly, it played a pivotal part in the initiation and progression of HCC. Nonetheless, no studies were found on its influences in HCC and the molecular mechanism. The miRNAs perform their functions by entirely or partly binding to the target genes, thereby resulting in the degradation or translational control of the target genes. Furthermore, miRNA would participate in the biological behaviors such as the proliferation of tumor cells, invasion, metastasis and so on [@B49]-[@B51]. The binding of miRNA to target genes had been sufficiently studied, and the prediction of miR-196b-5p target genes was available in many online databases [@B52]. In this study, taking advantage of 12 online software, we researchers predicted the miR-196b-5p target genes, then selecting those genes appearing in at least 5 software. Next, we combined the genes and the down-regulated mRNAs in TCGA, acquiring the 107 overlapping genes that could be used as possible target genes of miR-196b-5p. Previous studies reported that miR-196b-5p could influence the invasion of tumor cells, metastasis, resistance to drugs, etc. by targeting the downstream target mRNAs and relevant signal transduction pathways. For instance, results of Ren et al. suggested that miR-196b-5p could cause the resistance of colon cancer cells to 5-fluorouracil via STAT3 signal transduction pathway [@B34]. Stiegelbauer et al. put forth that invasion of colon cancer cells and distant metastasis could be controlled by miR-196b-5p targeting HOXB7 and GALNT5 [@B36]. In order to clarify the molecular mechanism of miR-196b-5p target genes in HCC, we carried out GO and DO annotations, KEGG pathway enrichment analyses, PPI network construction of the 107 potential target genes, which could elucidate the related pathways and possible biological roles of the potential target genes. The GO annotation unveiled that the top-ranked terms in biological process, cellular component and molecular function were single-organism catabolic process, neuronal cell body and transmembrane receptor protein kinase activity, respectively. The most relevant disease in DO annotation was arteriosclerosis. The tryptophan metabolism pathway ranked first in KEGG pathway enrichment analysis. The PPI network showed that IGF1, FOXO1, AR and FOS were mostly likely to become the core genes of miR-196b-5p potential target genes, which required further experiments for validation.

In this study, we, by means of qRT-PCR, TCGA sequencing data and GEO microarrays, confirmed that miR-196b-5p was expressed remarkably higher in HCC tissues rather than in healthy liver tissues. Moreover, miR-196b-5p expression level had correlations with the clinicopathological parameters such as vascular invasion of HCC. GO annotation revealed that the top-ranked terms in biological process, cellular component and molecular function were single-organism catabolic process, neuronal cell body and transmembrane receptor protein kinase activity, respectively. The most relevant disease in DO annotation was arteriosclerosis. The tryptophan metabolism pathway ranked first in KEGG pathway enrichment analysis. PPI network showed that IGF1, FOXO1, AR and FOS were mostly likely to become the core genes of miR-196b-5p potential target genes, which however required further experiments for validation.
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![The expression level and ROC curve analysis of miR-196b-5p in HCC based on qRT-PCR. **A**: miR-196b-5p expression level in HCC was higher than in adjacent tissues. **B**: ROC curve analysis of miR-196b-5p for discriminating HCC from adjacent tissues.](jcav10p5355g001){#F1}

![The expression level and ROC curve analysis of miR-196b-5p in HCC based on TCGA database. **A**: miR-196b-5p expression level in HCC was higher than in normal liver tissues. **B**: ROC curve analysis of miR-196b-5p for discriminating HCC from normal liver tissues.](jcav10p5355g002){#F2}

![Flow chart of study selection for miR-196b-5p microarray data based on GEO datasets.](jcav10p5355g003){#F3}

![The expression data of miR-196b-5p in HCC in ten microarrays from GEO datasets. **A**: the expression level of miR-196b-5p from GSE6857. **B**: the expression level of miR-196b-5p from GSE12717. **C**: the expression level of miR-196b-5p from GSE21362. **D**: the expression level of miR-196b-5p from GSE22058. **E**: the expression level of miR-196b-5p from GSE31383. **F**: the expression level of miR-196b-5p from GSE41874. **G**: the expression level of miR-196b-5p from GSE54751. **H**: the expression level of miR-196b-5p from GSE57555. **I**: the expression level of miR-196b-5p from GSE69580. **J**: the expression level of miR-196b-5p from GSE74618.](jcav10p5355g004){#F4}

![The ROC curves of miR-196b-5p in HCC in ten microarrays from GEO datasets. **A**: the ROC curve of miR-196b-5p from GSE6857. **B**: the ROC curve of miR-196b-5p from GSE12717. **C**: the ROC curve of miR-196b-5p from GSE21362. **D**: the ROC curve of miR-196b-5p from GSE22058. **E**: the ROC curve of miR-196b-5p from GSE31383. **F**: the ROC curve of miR-196b-5p from GSE41874. **G**: the ROC curve of miR-196b-5p from GSE54751. **H**: the ROC curve of miR-196b-5p from GSE57555. **I**: the ROC curve of miR-196b-5p from GSE69580. **J**: the ROC curve of miR-196b-5p from GSE74618.](jcav10p5355g005){#F5}

![Forest plot of studies evaluating standard mean difference of miR-196b-5p expression between HCC group and non-tumor group based on TCGA, GEO and qRT-PCR.](jcav10p5355g006){#F6}

![Sensitivity analysis and the forest plot after sensitivity analysis. **A**: sensitivity analysis of Meta-analysis of the expression level of miR-196b-5p in HCC group and in non-tumor group based on TCGA, GEO and qRT-PCR. **B**: forest plot of miR-196b-5p expression between HCC group and non-tumor group after removing the study of GSE6857 and GSE22058.](jcav10p5355g007){#F7}

![Funnel plot for publication bias test after Meta-analysis of the expression level of miR-196b-5p based on TCGA, GEO and qRT-PCR.](jcav10p5355g008){#F8}

![SROC curve analysis of miR-196b-5p for discriminating HCC from normal liver tissues based on TCGA, GEO and qRT-PCR.](jcav10p5355g009){#F9}

![The volcano plot of mRNA expression in HCC based on TCGA database. The pink dots represent up-regulated genes, the green dots represent down-regulated genes and the blue dots are non-differentially expressed genes.](jcav10p5355g010){#F10}

![DO functional annotation of the 107 potential target genes of miR-196b-5p, circles represent diseases and edges represent disease-disease associations.](jcav10p5355g011){#F11}

![Top 10 DO functional annotation terms of the 107 potential target genes of miR-196b-5p, color tints represent the P-values and size of the circle represent the number of selected genes in the pathway.](jcav10p5355g012){#F12}

![PPI network of the 107 potential target genes of miR-196b-5p constructed by STRING online database, nodes represent proteins and edges represent protein-protein associations.](jcav10p5355g013){#F13}

###### 

The relationships between miR-196b-5p expression and the clinicopathologic parameters by qRT-PCR

  Clinicopathologic parameters                   miR-196b-5p expression   P value   
  ----------------------------------- ---------- ------------------------ --------- ---------
  Sex                                 Male       29                       27        
                                      Female     5                        6         0.701
  Age                                 \<60       27                       27        
                                      ≥60        7                        6         0.803
  Tumor size (cm)                     ≥5         27                       18        
                                      \<5        7                        15        0.03\*
  Tumor nodule                        Single     25                       31        
                                      Multiple   9                        2         0.024\*
  Vascular invasion                   Yes        17                       8         
                                      No         17                       25        0.029\*
  Capsular invasion                   Yes        12                       4         
                                      No         22                       29        0.026\*
  HBV infection                       Yes        28                       28        
                                      No         6                        5         0.783
  HCV infection                       Yes        1                        1         
                                      No         31                       32        1
  Cirrhosis                           Yes        19                       17        
                                      No         15                       16        0.72
  Portal vein tumor thrombus (PVTT)   Yes        5                        2         
                                      No         29                       31        0.449
  AFP (ng/ml)                         ≥400       16                       11        
                                      \<400      18                       21        0.295
  nm23                                Positive   31                       33        
                                      Negative   3                        0         0.248
  P53                                 Positive   25                       27        
                                      Negative   9                        6         0.416
  P21                                 Positive   5                        3         
                                      Negative   29                       30        0.74
  VEGF                                Positive   16                       17        
                                      Negative   17                       16        0.806
  Ki-67                               High       18                       19        
                                      Low        14                       13        0.8
  CD34                                High       15                       19        
                                      Low        9                        3         0.066
  Pathologic grading                  I-II       18                       21        
                                      III-IV     16                       12        0.375
  Child-Pugh class                    A          21                       18        
                                      B          3                        2         1
  BCLC stage                          0          0                        2         
                                      A          12                       9         
                                      B          11                       7         
                                      C          1                        2         0.356

**Note:** HCC, hepatocellular carcinoma; AFP, α-fetoprotein; nm23, Non-metastasis 23; VEGF, vascular endothelial growth factor; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona Clinic Liver Cancer; \*P\<0.05.

###### 

The relationships between miR-196b-5p expression and the clinicopathologic parameters in TCGA

  Clinicopathologic parameters   Number of cases   miR-196b-5p expression   P value     
  ------------------------------ ----------------- ------------------------ ----------- ---------
  Tissues                        HCC               369                      4.49±2.42   0.003\*
                                 Normal controls   49                       3.47±0.50   
  Sex                            Male              250                      4.31±2.42   0.035\*
                                 Female            119                      4.88±2.40   
  Age                            \<60              170                      4.30±2.41   0.168
                                 ≥60               198                      4.65±2.43   
  Pathologic grading             I\~II             228                      4.28±2.37   0.041\*
                                 III\~IV           137                      4.81±2.44   
  Stage                          I\~II             256                      4.52±2.44   0.97
                                 III\~IV           87                       4.51±2.41   
  T                              TX                1                        4.16        
                                 T1                180                      4.34±2.37   0.524
                                 T2-4              186                      4.62±2.45   
  N                              NX                111                      4.10±2.30   
                                 N0                253                      4.67±2.46   0.078
                                 N1                4                        3.42±1.70   
  M                              MX                98                       4.09±2.29   
                                 M0                267                      4.64±2.47   0.148
                                 M1                4                        4.84±1.09   
  Vascular invasion              Yes               110                      4.93±2.56   0.023\*
                                 No                204                      4.27±2.34   
  Cirrhosis                      Yes               6                        3.44±2.56   0.272
                                 No                344                      4.53±2.39   
  Drinking                       Yes               117                      4.49±2.32   0.908
                                 No                233                      4.52±2.44   
  Smoking                        Yes               17                       4.82±2.57   0.579
                                 No                333                      4.49±2.39   
  HBV infection                  Yes               107                      4.55±2.58   0.828
                                 No                243                      4.49±2.31   
  HCV infection                  Yes               55                       4.53±2.53   0.948
                                 No                295                      4.50±2.37   

**Note:** HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; HBV, hepatitis B virus; HCV, hepatitis C virus; \*P\<0.05.

###### 

The basic features of 10 microarrays of expression profiling of miR-196b-5p form GEO database

  Series     Platform                     Country/Region   Citation                   Number of samples   miR-196b-5p expression (Mean ± SD)                  
  ---------- ---------------------------- ---------------- -------------------------- ------------------- ------------------------------------ -------------- ----------------
                                                                                      HCC                 Normal control                       HCC            Normal control
  GSE6857    GPL4700                      USA              Budhu et al. (2008)        241                 241                                  10.322±0.607   10.113±0.575
  GSE12717   GPL7274                      USA              Su et al. (2009)           10                  6                                    4.742±0.629    3.987±0.544
  GSE21362   GPL10312                     Japan            Sato et al. (2011)         73                  73                                   1.686±1.463    1.053±0.957
  GSE22058   GPL10457, GPL6793, GPL9733   USA              Burchard et al. (2010)     96                  96                                   0.416±0.214    0.265±0.020
  GSE31383   GPL10122                     USA              Wang et al. (2012)         9                   10                                   1.084±1.584    0.223±0.081
  GSE41874   GPL7722                      Japan            None                       3                   3                                    1.171±0.129    1.359±0.397
  GSE54751   GPL18262                     USA              Shen et al. (2015)         9                   10                                   1.002±0.002    1.000±0.000
  GSE57555   GPL18044, GPL16699           Japan            Murakami et al. (2015)     5                   16                                   0.975±0.004    0.969±0.015
  GSE69580   GPL10850                     Taiwan           None                       5                   5                                    2.938±1.832    0.824±0.527
  GSE74618   GPL14613                     Spain            Villanueva et al. (2016)   218                 10                                   1.380±0.483    1.227±0.158

**Note:** HCC, hepatocellular carcinoma; USA, United States of America; SMD, standard mean difference.

###### 

A total of 107 potential target genes of miR-196b-5p

  Gene names                                                         
  ------------ ---------- ---------- ---------- ---------- --------- ---------
  UROC1        SPATA18    PTPRD      NFAM1      IGFBP3     DMD       BCO2
  TRIB1        SOWAHC     PRKCB      NAALADL2   IGF1       DLGAP2    BACH2
  TMEM56       SOCS2      PPARGC1A   MTTP       HAAO       CXCL12    AXL
  TMEM25       SLC46A3    PLIN2      MMAA       GYS2       CTBS      ATP13A4
  TMEM220      SLC41A2    PLCXD3     MEGF10     GJB2       CR1       ATP11C
  TGFBR3       SLC38A4    PDGFRA     MCC        FRMD4B     CPN2      AR
  TBX15        SLC38A2    PDE7B      MBNL2      FREM2      CPEB3     APOF
  TAPT1        SLC35D1    PDE2A      MBL2       FOXO1      COLEC11   ALDOB
  SYT9         SLC31A1    PDE11A     MASP1      FOS        COBLL1    ALDH6A1
  SYNPO2       SIGLEC1    PANK1      LPIN2      FAM46A     CHRM2     ALDH1B1
  SULT2A1      SERPINE1   PALM2      KMO        ESR1       CDH19     ACVR1C
  ST6GAL2      SERPINB9   PAIP2B     KLHL15     EPM2A      CD302     
  ST3GAL6      SERPINB8   OAS2       KLF11      EPB41L4B   CD300E    
  SRD5A1       RSAD2      NTN4       INMT       ELMSAN1    CCL23     
  SPTBN2       RET        NRXN1      INHBC      EDNRB      CBFA2T3   
  SPRYD4       RBMS3      NRBF2      IL6ST      DPYD       BMPER     

###### 

GO annotation and KEGG pathway enrichment analysis of 107 potential target genes of miR-196b-5p

  ID                       Term                                                           Count   \%     P Value      Genes
  ------------------------ -------------------------------------------------------------- ------- ------ ------------ -------------------------------------------------------------------------------------
  **Biological Process**                                                                                              
  GO:0044712               single-organism catabolic process                              19      17.8   1.94E-06     ALDH6A1, PLCXD3, SULT2A1, ALDOB, IGF1, PDE11A, KMO, CBFA2T3, LPIN2, PPARGC1A, etc.
  GO:0009605               response to external stimulus                                  28      26.2   5.53E-05     MBL2, SLC38A2, MASP1, IL6ST, RSAD2, FOXO1, OAS2, FAM46A, CXCL12, TRIB1, etc.
  GO:0044710               single-organism metabolic process                              43      40.2   6.37E-05     PLCXD3, IL6ST, ALDOB, PDE11A, FOXO1, KMO, OAS2, CBFA2T3, ACVR1C, EDNRB, etc.
  GO:0051094               positive regulation of developmental process                   19      17.8   6.86E-05     TAPT1, AR, PTPRD, RET, CPEB3, IL6ST, AXL, IGF1, ATP11C, NRXN1, etc.
  GO:1901701               cellular response to oxygen-containing compound                17      15.9   9.21E-05     RET, SOCS2, CPEB3, KLF11, ESR1, AXL, FOXO1, PPARGC1A, TRIB1, EDNRB, etc.
  GO:0055086               nucleobase-containing small molecule metabolic process         15      14     0.00010186   ALDH6A1, SULT2A1, ALDOB, PDE11A, IGF1, KMO, OAS2, CBFA2T3, PPARGC1A, EDNRB, etc.
  GO:0051239               regulation of multicellular organismal process                 32      29.9   0.00010961   TAPT1, IL6ST, CPEB3, RSAD2, FOXO1, FAM46A, CXCL12, MEGF10, FOS, EDNRB, etc.
  GO:0048806               genitalia development                                          5       4.7    0.00012226   AR, AXL, ESR1, SRD5A1, GJB2
  GO:1901700               response to oxygen-containing compound                         22      20.6   0.00012321   RET, SOCS2, CPEB3, KLF11, ESR1, AXL, FOXO1, PPARGC1A, CXCL12, TRIB1, etc.
  GO:0048585               negative regulation of response to stimulus                    21      19.6   0.00014142   CR1, AR, MASP1, SOCS2, IL6ST, EPM2A, ESR1, FOXO1, IGF1, NRXN1, etc.
  **Cellular Component**                                                                                              
  GO:0043025               neuronal cell body                                             10      9.3    0.0006596    RET, SLC38A2, CHRM2, IL6ST, SPTBN2, PDE11A, SRD5A1, NRXN1, SLC31A1, PPARGC1A
  GO:0071944               cell periphery                                                 46      43     0.00115965   SLC38A4, SLC38A2, IL6ST, CPEB3, SYT9, MEGF10, CXCL12, ACVR1C, EDNRB, PLIN2, etc.
  GO:0005615               extracellular space                                            19      17.8   0.00128717   MBL2, MASP1, IL6ST, AXL, IGF1, CXCL12, CPN2, SERPINB9, CCL23, BMPER, etc.
  GO:0044297               cell body                                                      10      9.3    0.00170277   RET, SLC38A2, CHRM2, IL6ST, SPTBN2, PDE11A, SRD5A1, NRXN1, SLC31A1, PPARGC1A
  GO:0036477               somatodendritic compartment                                    11      10.3   0.00454342   RET, SLC38A2, CHRM2, CPEB3, IL6ST, SPTBN2, PDE11A, SRD5A1, NRXN1, SLC31A1, PPARGC1A
  GO:0005886               plasma membrane                                                43      40.2   0.004909     SLC38A4, SLC38A2, IL6ST, CPEB3, SYT9, MEGF10, CXCL12, ACVR1C, EDNRB, PLIN2, etc.
  GO:0097458               neuron part                                                    16      15     0.00856024   RET, SLC38A2, CPEB3, DLGAP2, IL6ST, SYT9, PDE11A, NRXN1, PPARGC1A, FOS, etc.
  GO:0044459               plasma membrane part                                           25      23.4   0.01229329   SLC38A4, SLC38A2, CPEB3, IL6ST, CXCL12, MEGF10, ACVR1C, EDNRB, DMD, SLC31A1, etc.
  GO:0044425               membrane part                                                  52      48.6   0.02036989   IL6ST, CPEB3, SYT9, CXCL12, MEGF10, ACVR1C, EDNRB, TMEM56, AR, RET, etc.
  GO:0097060               synaptic membrane                                              6       5.6    0.02099924   PDE2A, CHRM2, DLGAP2, CPEB3, DMD, NRXN1
  **Molecular Function**                                                                                              
  GO:0019199               transmembrane receptor protein kinase activity                 5       4.7    0.00122381   RET, PDGFRA, AXL, TGFBR3, ACVR1C
  GO:0004115               3\',5\'-cyclic-AMP phosphodiesterase activity                  3       2.8    0.00320233   PDE7B, PDE2A, PDE11A
  GO:0019838               growth factor binding                                          5       4.7    0.00612277   IL6ST, PDGFRA, TGFBR3, IGFBP3, ACVR1C
  GO:0005102               receptor binding                                               17      15.9   0.00806588   MBL2, AR, PTPRD, SOCS2, IL6ST, IGF1, NRXN1, CXCL12, PRKCB, EDNRB, etc.
  GO:0004114               3\',5\'-cyclic-nucleotide phosphodiesterase activity           3       2.8    0.01024124   PDE7B, PDE2A, PDE11A
  GO:0004112               cyclic-nucleotide phosphodiesterase activity                   3       2.8    0.01098852   PDE7B, PDE2A, PDE11A
  GO:0008081               phosphoric diester hydrolase activity                          4       3.7    0.01599651   PLCXD3, PDE7B, PDE2A, PDE11A
  GO:0004118               cGMP-stimulated cyclic-nucleotide phosphodiesterase activity   2       1.9    0.01696476   PDE2A, PDE11A
  GO:0030246               carbohydrate binding                                           6       5.6    0.01739252   MBL2, SIGLEC1, EPM2A, ALDOB, COLEC11, CD302
  GO:0005126               cytokine receptor binding                                      6       5.6    0.01979523   CCL23, SOCS2, IL6ST, INHBC, TGFBR3, CXCL12
  **KEGG pathway**                                                                                                    
  hsa00380                 tryptophan metabolism                                          4       3.7    0.00308774   ALDH1B1, HAAO, KMO, INMT
  hsa05200                 pathways in cancer                                             9       8.4    0.00752836   EDNRB, FOS, AR, RET, PDGFRA, FOXO1, IGF1, CXCL12, PRKCB
  hsa04610                 complement and coagulation cascades                            4       3.7    0.01409894   MBL2, CR1, MASP1, SERPINE1
  hsa00410                 beta-alanine metabolism                                        3       2.8    0.02166778   ALDH6A1, ALDH1B1, DPYD
  hsa05215                 prostate cancer                                                4       3.7    0.02678936   AR, PDGFRA, FOXO1, IGF1
  hsa05032                 morphine addiction                                             4       3.7    0.02920649   PDE7B, PDE2A, PDE11A, PRKCB

**Note:** GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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